Laboratory studies and Pompe disease: from suspicion to therapy monitoring
- Authors: Savost’yanov K.V.1,2, Nikitin S.S.3,4, Karpacheva K.E.5,6,7
-
Affiliations:
- Laboratory of Molecular Genetics and Cell Biology Scientific Center of Children’s Health
- Build 1, 2 Lomonosovskiy prospekt, Moscow, 119991, Russia
- Society of Experts in Neuromuscular Diseases, Medical Center “Practical Neurology”
- Build. 2, 17 Krzhizhanovskogo St., Моscow, 117218, Russia
- Representative Office, Sanofi Aventis Group
- 22 Tverskaya St., Moscow, 125009, Russia
- Issue: Vol 6, No 1 (2016)
- Pages: 54-62
- Section: LECTURES AND REVIEWS
- Published: 29.03.2016
- URL: https://nmb.abvpress.ru/jour/article/view/138
- DOI: https://doi.org/10.17650/2222-8721-2016-6-1-54-62
- ID: 138
Cite item
Full Text
Abstract
Pompe disease (PD) is a rare, progressive, commonly fatal inherited autosomal recessive disease that is difficult to diagnose due to its obvious clinical heterogeneity and low awareness among physicians. Access to the laboratory diagnosis of rare diseases increases every year. In the past several years, Russian and foreign laboratories have achieved considerable success in accelerating and improving the diagnostic accuracy of PD. Unfortunately, the Russian-language literature contains scarce relevant information on the laboratory diagnosis of PD. This review is to fill up this gap.
About the authors
K. V. Savost’yanov
Laboratory of Molecular Genetics and Cell Biology Scientific Center of Children’s Health; Build 1, 2 Lomonosovskiy prospekt, Moscow, 119991, Russia
Email: fake@neicon.ru
Russian Federation
S. S. Nikitin
Society of Experts in Neuromuscular Diseases, Medical Center “Practical Neurology”; Build. 2, 17 Krzhizhanovskogo St., Моscow, 117218, Russia
Email: fake@neicon.ru
Russian Federation
K. E. Karpacheva
Representative Office, Sanofi Aventis Group; 22 Tverskaya St., Moscow, 125009, Russia;
Author for correspondence.
Email: klavdiya.karpacheva@sanofi.com
Russian Federation
References
Supplementary files



